newsfilter
← Latest News
GlobeNewswire·

Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

  • Syndax Pharmaceuticals reported total revenue of $68.7 million for the fourth quarter of 2025 and $172.4 million for the full year 2025.
  • Revuforj (revumenib) generated $44.2 million in net revenue in Q4 2025, a 38% increase from Q3 2025, and $124.8 million for the full year 2025.
  • Niktimvo (axatilimab-csfr) generated $56.0 million in net revenue in Q4 2025, a 22% increase from Q3 2025, and $151.6 million for the full year 2025.
  • Syndax recorded $42.4 million in Niktimvo collaboration revenue for the full year 2025, representing its 50% share of the net commercial profit.
  • The company completed enrollment in its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis (IPF) with topline data expected in Q4 2026.
  • Revuforj prescriptions reached approximately 1,150 in Q4 2025, marking a 35% increase from the prior quarter.
  • Syndax initiated the REVEAL-ND Phase 3 trial for Revuforj in newly diagnosed NPM1m AML patients in November 2025.
  • The company received the 'Best New Drug' award for Revuforj at the 2025 Scrip Awards.
  • Multiple clinical trials for Revuforj are ongoing, including REVEAL-ND, EVOLVE-2, SAVE, BEAT AML, and post-transplant maintenance studies.
  • The RAVEN Phase 2 trial for Revuforb is expected to initiate in the second half of 2026.
  • Syndax reported a net loss of $68.0 million for Q4 2025 ($0.78 per share) and $285.4 million for the full year 2025 ($3.29 per share).
  • Research and development expenses increased to $78.6 million in Q4 2025 and $258.8 million for the full year 2025.
  • Selling, general, and administrative expenses increased to $49.9 million in Q4 2025 and $179.7 million for the full year 2025.
  • As of December 31, 2025, Syndax held $394.1 million in cash, cash equivalents, and short-term investments.
  • The company expects total operating expenses for 2026 to be approximately $400 million, excluding $50 million in non-cash stock compensation.
  • Syndax anticipates reaching profitability in the coming years driven by product revenue, collaboration revenue, and interest income.
  • Management hosted a conference call on February 26, 2026, to discuss the financial results and business updates.